While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Brightseed Co-Founder Sofia Elizondo breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants.
On this episode of Cheddar Innovates: Brightseed Co-Founder breaks down what plant bioactives are, and how they're using the latest technology to study human's biological connections with plants; Esper Bionics CEO breaks down how they re creating a mind-controlled bionic hand that guest smarter the more you use it; Cheddar gets a look at Curiosity Stream's 'Capturing A Black Hole In Our Milky Way.'
Hilary Kearney, Founder of Girl Next Door Honey, joined Closing Bell to discuss her partnership with Comvita to save the important pollinators, as bee colonies are on the decline across the United States.
Hurricane climatologist Jill Trepanier joined Cheddar News to discuss NOAA's announced prediction for an above-normal hurricane season and what it might mean for people in the United States. "I think it's important that people who maybe haven't been used to having extreme weather events related to say tropical cycles and tropical systems, like thinking New Jersey, Northeastern seaboard, that area may get more action than they're used to in the past," she said.
Dr. Jarrad Aguirre, Co-Founder and CEO of Miga Health, joins Cheddar News' Closing Bell, where he says his company is looking to establish the future of heart health and points to how 80% of premature heart attacks and strokes are preventable.
On this episode of Cheddar Reveals, David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering outlines the viability of solar geoengineering as a solution to help reverse the effects of global warming; Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, discusses which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change; Cheddar gets a look at Curiosity Stream's 'Changing Ocean Asia.'
David Keith, Professor of Applied Physics at the Harvard School of Engineering and Applied Sciences and Professor of Public Policy at the Harvard Kennedy School, and founder of Carbon Engineering joins Cheddar Reveals to outline the viability of solar geoengineering as a solution to help reverse the effects of global warming.
Lena Geraghty, Sustainability & Urban Innovation Director at National League of Cities, joins Cheddar News to discuss which U.S. cities are safest from global warming and how the real estate market will be impacted from the effects of climate change.
Peggy Whitson, Director of Human Space Flight, Axiom Space, joins Cheddar Innovates to discuss Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space.
On this episode of Cheddar Innovates, Peggy Whitson, Director of Human Space Flight, Axiom Space, breaks down Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space; William Li and Danielle Chang, co-founders of The Hao Life, discuss how they're shaking up the $71 billion supplement industry by putting a modern spin on traditional natural Chinese remedies; Cheddar gets a look at Curiosity Stream's 'Sagrada Familia: Gaudi's Challenge.'
